Michael Ryskin

Stock Analyst at B of A Securities

(1.47)
# 3,486
Out of 5,165 analysts
41
Total ratings
52%
Success rate
-2.59%
Average return

Stocks Rated by Michael Ryskin

Recursion Pharmaceuticals
Feb 26, 2026
Maintains: Neutral
Price Target: $7$6
Current: $3.40
Upside: +76.47%
Zoetis
Feb 13, 2026
Maintains: Neutral
Price Target: $135$140
Current: $121.74
Upside: +15.00%
Schrödinger
Dec 15, 2025
Upgrades: Buy
Price Target: $24
Current: $12.51
Upside: +91.85%
Revvity
Sep 22, 2025
Maintains: Buy
Price Target: $110$99
Current: $88.51
Upside: +11.85%
Tempus AI
Jun 25, 2025
Maintains: Neutral
Price Target: $68$70
Current: $50.72
Upside: +38.01%
IDEXX Laboratories
Apr 21, 2025
Maintains: Neutral
Price Target: $535$475
Current: $592.23
Upside: -19.79%
Maravai LifeSciences Holdings
Mar 3, 2025
Maintains: Buy
Price Target: $9$8
Current: $3.12
Upside: +156.82%
Align Technology
Dec 13, 2024
Maintains: Underperform
Price Target: $200$206
Current: $176.33
Upside: +16.83%
Guardant Health
Jul 18, 2024
Maintains: Buy
Price Target: $28$40
Current: $87.73
Upside: -54.41%
Alight
Jun 25, 2024
Maintains: Buy
Price Target: $10$9.5
Current: $0.79
Upside: +1,105.12%
Maintains: Buy
Price Target: $27$24
Current: $6.75
Upside: +255.56%
Maintains: Buy
Price Target: $27$24
Current: $7.78
Upside: +208.48%
Downgrades: Underperform
Price Target: $17$10
Current: $2.67
Upside: +274.53%